MX2023004857A - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). - Google Patents

Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Info

Publication number
MX2023004857A
MX2023004857A MX2023004857A MX2023004857A MX2023004857A MX 2023004857 A MX2023004857 A MX 2023004857A MX 2023004857 A MX2023004857 A MX 2023004857A MX 2023004857 A MX2023004857 A MX 2023004857A MX 2023004857 A MX2023004857 A MX 2023004857A
Authority
MX
Mexico
Prior art keywords
crystalline forms
sgc stimulator
present disclosure
sgc
stimulator
Prior art date
Application number
MX2023004857A
Other languages
English (en)
Inventor
Kwame W Nti-Addae
Thomas Storz
Leena Kumari Prasad
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2023004857A publication Critical patent/MX2023004857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción se relaciona con formas cristalinas de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)im idazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente descripción también provee composiciones farmacéuticamente aceptables que comprenden las formas cristalinas y métodos para usar las composiciones en el tratamiento de diversas afecciones.
MX2023004857A 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). MX2023004857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
MX2023004857A true MX2023004857A (es) 2023-11-24

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2023004858A MX2023004858A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2020009183A MX2020009183A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004855A MX2023004855A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004857A MX2023004857A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004856A MX2023004856A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2023004858A MX2023004858A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2020009183A MX2020009183A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
MX2023004855A MX2023004855A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004856A MX2023004856A (es) 2018-03-07 2019-03-07 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Country Status (20)

Country Link
US (2) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR20200128708A (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724B2 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
IL (1) IL276853A (es)
MA (1) MA54638A (es)
MX (5) MX2023004858A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100092QA (en) * 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
WO2024131850A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1095016T3 (da) 1998-07-08 2006-03-13 Sanofi Aventis Deutschland Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2564503T3 (es) 2010-05-27 2016-03-23 Merck Sharp & Dohme Corp. Activadores de la guanilato-ciclasa soluble
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016087342A1 (de) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
DK3507291T3 (da) 2016-09-02 2021-08-30 Cyclerion Therapeutics Inc Kondenserede bicykliske sgc-stimulatorer

Also Published As

Publication number Publication date
MA54638A (fr) 2021-11-10
MX2023004855A (es) 2023-11-24
JP2021515015A (ja) 2021-06-17
EP3762389B1 (en) 2024-02-28
BR112020018212A2 (pt) 2020-12-29
CL2020002284A1 (es) 2020-11-27
US20230095799A1 (en) 2023-03-30
CA3092683A1 (en) 2019-09-12
MX2023004856A (es) 2023-11-24
TW201940487A (zh) 2019-10-16
TWI823903B (zh) 2023-12-01
CO2020012493A2 (es) 2020-10-30
EA202092109A1 (ru) 2021-03-04
WO2019173551A1 (en) 2019-09-12
AU2019231724A1 (en) 2020-10-08
CN111836812A (zh) 2020-10-27
WO2019173551A8 (en) 2020-06-11
CR20200458A (es) 2020-11-09
PH12020551394A1 (en) 2021-11-22
JP7423539B2 (ja) 2024-01-29
CL2021003530A1 (es) 2022-08-19
AU2019231724B2 (en) 2024-06-27
KR20200128708A (ko) 2020-11-16
CL2021000301A1 (es) 2021-06-18
SG11202008641WA (en) 2020-10-29
US11466015B2 (en) 2022-10-11
MX2023004858A (es) 2023-11-24
MX2020009183A (es) 2020-10-08
IL276853A (en) 2020-10-29
CL2021003536A1 (es) 2022-08-19
EP3762389A1 (en) 2021-01-13
US20210115050A1 (en) 2021-04-22
PE20210124A1 (es) 2021-01-19
CL2021003531A1 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
PH12020551394A1 (en) CRYSTALLINE FORMS OF AN sGC STIMULATOR
AR113758A1 (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2018002017A (es) Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
MX2018003186A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[ 4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer.
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
IL172192A0 (en) Pyridino [1,2 - a] pyrimidin - 4 - one compounds as anticancer agents
MX2018004954A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer.
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
WO2004073628A3 (en) Novel compounds
MXPA04010307A (es) Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
UA93522C2 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones
MX2022006934A (es) Inhibidor de aldosterona sintasa.
WO2022058745A3 (en) Imidazo[1,2-a]pyridine compounds and their use in therapy
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
MX2021002794A (es) Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma.
CR20200457A (es) Proceso para la preparación de estumaladores de guanilato ciclasa soluble
WO2018226875A3 (en) Methods and medicaments for the treatment of renal cell carcinoma